CBA-1535

Chiome Bioscience Inc. · Phase 1 active Small molecule

At a glance

Generic name	CBA-1535
Sponsor	Chiome Bioscience Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CBA-1535 CI brief — competitive landscape report
CBA-1535 updates RSS · CI watch RSS
Chiome Bioscience Inc. portfolio CI